ZimVie Inc., a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies. The company also provides MIS solutions, such as Vital MIS and Timberline; and motion preservation solutions, including Mobi-C and The Tether. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.
IPO Year:
Exchange: NASDAQ
Website: https://www.zimvie.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/16/2024 | $20.00 | Hold → Buy | Needham |
| 11/16/2023 | Hold | Needham | |
| 12/21/2022 | $9.00 | Underweight | Barclays |
| 6/17/2022 | $20.00 | Neutral | JP Morgan |
| 3/18/2022 | Neutral | Guggenheim |
4 - ZimVie Inc. (0001876588) (Issuer)
4 - ZimVie Inc. (0001876588) (Issuer)
4 - ZimVie Inc. (0001876588) (Issuer)
4 - ZimVie Inc. (0001876588) (Issuer)
4 - ZimVie Inc. (0001876588) (Issuer)
4 - ZimVie Inc. (0001876588) (Issuer)
4 - ZimVie Inc. (0001876588) (Issuer)
4 - ZimVie Inc. (0001876588) (Issuer)
4 - ZimVie Inc. (0001876588) (Issuer)
4 - ZimVie Inc. (0001876588) (Issuer)
Third Party Net Sales from Continuing Operations of $103.2 millionNet Loss from Continuing Operations of $(3.0) million; Net Loss margin of (3.0%) Adjusted EBITDA[1] from Continuing Operations of $13.1 million; Adjusted EBITDA[1] margin of 12.7%GAAP diluted EPS from Continuing Operations of $(0.11) and adjusted diluted EPS of $0.12 PALM BEACH GARDENS, Fla., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended September 30, 2024. Management will host a corresponding conference call today, October 30, 2024, at 4:30 p.m. Eastern Time. "In the third quarter we saw an improvement
PALM BEACH GARDENS, Fla., Oct. 16, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com About ZimVie ZimVie is a global life sciences leader in the dental market that develops, manu
Third Party Net Sales from Continuing Operations of $116.8 millionNet Loss from Continuing Operations of $(9.6) million; Net Loss margin of (8.2%) Adjusted EBITDA[1] from Continuing Operations of $16.1 million; Adjusted EBITDA[1] margin of 13.8%Reduced debt to $235.1 million, ended quarter with cash balance from Continuing Operations of $78.6 million PALM BEACH GARDENS, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended June 30, 2024. Management will host a corresponding conference call today, August 1, 2024, at 4:30 p.m. Eastern Time. "We continued to execute in the
PALM BEACH GARDENS, Fla., July 18, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the second quarter 2024 after market close on Thursday, August 1, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com About ZimVie ZimVie is a global life sciences leader in the dental market that develops, manufa
Third Party Net Sales from Continuing Operations of $118.2 millionNet Loss from Continuing Operations of ($11.5) million; Net Loss margin of (9.7%) Adjusted EBITDA[1] from Continuing Operations of $12.5 million; Adjusted EBITDA[1] margin of 10.5%Completed sale of spine business for $375 million and repaid $275 million of debt on April 1, 2024 PALM BEACH GARDENS, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2024. Management will host a corresponding conference call today, May 8, 2024, at 4:30 p.m. Eastern Time. "We have driven great progress in 2024 to
PALM BEACH GARDENS, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the first quarter 2024 after market close on Wednesday, May 8, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com About ZimVie ZimVie is a global life sciences leader in the dental market that develops, manufact
H.I.G. Capital ("H.I.G."), a leading global alternative investment firm with $60 billion of capital under management, is pleased to announce that one of its affiliates has completed the acquisition of the Spine division of ZimVie, Inc (("ZimVie", NYSE:ZIMV). The acquired business will operate as an independent entity and has been renamed Highridge Medical ("Highridge" or the "Company"). Headquartered in Westminster, CO, Highridge is a leader in the global spinal device market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to treat a wide range of spine pathologies. The Company has a market-leading portfolio of bone healing therapies
FY 2023 Third Party Net Sales from Continuing Operations of $457.2 millionFY 2023 Third Party Net Sales from Discontinued Operations of $409.2 millionUpdated Reporting Framework: Continuing Operations consists of the Dental Business and the majority of Corporate while Discontinued Operations consists of the Spine Business Advancing plan to complete sale of Spine Business for $375M in total consideration; sale remains on track to be completed in 1H 2024 WESTMINSTER, Colo., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental and spine markets, today reported financial results for the quarter and year ended December 31, 2023. Management
WESTMINSTER, Colo., Feb. 21, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the fourth quarter and full-year 2023 after market close on Wednesday, February 28, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com. About ZimVie ZimVie is a global life sciences leader in the dental and spine
Third Party Net Sales of $202.9 millionNet Loss of ($5.1) million; Net Loss Margin of (2.5%); Adjusted Net Income[1] of $2.2 millionDiluted EPS of ($0.19); Adjusted Diluted EPS[1] of $0.08Adjusted EBITDA[1] of $25.8 million; Adjusted EBITDA margin[1] of 12.7% Ending cash balance of $75.4M as of September 30, 2023 WESTMINSTER, Colo., Nov. 01, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental and spine markets, today reported financial results for the third quarter ended September 30, 2023. Management will host a corresponding conference call today, November 1, 2023, at 4:30 p.m. Eastern Time. "In the third quarter, we continued to make pr
10-Q - ZimVie Inc. (0001876588) (Filer)
8-K - ZimVie Inc. (0001876588) (Filer)
10-Q - ZimVie Inc. (0001876588) (Filer)
8-K - ZimVie Inc. (0001876588) (Filer)
SD - ZimVie Inc. (0001876588) (Filer)
8-K - ZimVie Inc. (0001876588) (Filer)
10-Q - ZimVie Inc. (0001876588) (Filer)
8-K - ZimVie Inc. (0001876588) (Filer)
8-K/A - ZimVie Inc. (0001876588) (Filer)
DEFA14A - ZimVie Inc. (0001876588) (Filer)
Needham upgraded ZimVie from Hold to Buy and set a new price target of $20.00
Needham initiated coverage of ZimVie with a rating of Hold
Barclays initiated coverage of ZimVie with a rating of Underweight and set a new price target of $9.00
JP Morgan initiated coverage of ZimVie with a rating of Neutral and set a new price target of $20.00
Guggenheim initiated coverage of ZimVie with a rating of Neutral
Third Party Net Sales from Continuing Operations of $103.2 millionNet Loss from Continuing Operations of $(3.0) million; Net Loss margin of (3.0%) Adjusted EBITDA[1] from Continuing Operations of $13.1 million; Adjusted EBITDA[1] margin of 12.7%GAAP diluted EPS from Continuing Operations of $(0.11) and adjusted diluted EPS of $0.12 PALM BEACH GARDENS, Fla., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended September 30, 2024. Management will host a corresponding conference call today, October 30, 2024, at 4:30 p.m. Eastern Time. "In the third quarter we saw an improvement
PALM BEACH GARDENS, Fla., Oct. 29, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced management will participate in the upcoming UBS Global Healthcare Conference. Management will be presenting on Tuesday, November 12, 2024 at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time. A live webcast of the event, as well as an archived recording will be available on ZimVie's investor website at investor.zimvie.com. About ZimVieZimVie is a global life sciences leader in the dental market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and r
PALM BEACH GARDENS, Fla., Oct. 16, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com About ZimVie ZimVie is a global life sciences leader in the dental market that develops, manu
Third Party Net Sales from Continuing Operations of $116.8 millionNet Loss from Continuing Operations of $(9.6) million; Net Loss margin of (8.2%) Adjusted EBITDA[1] from Continuing Operations of $16.1 million; Adjusted EBITDA[1] margin of 13.8%Reduced debt to $235.1 million, ended quarter with cash balance from Continuing Operations of $78.6 million PALM BEACH GARDENS, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended June 30, 2024. Management will host a corresponding conference call today, August 1, 2024, at 4:30 p.m. Eastern Time. "We continued to execute in the
PALM BEACH GARDENS, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced the release of its RealGUIDE® 5.4 software. The update is now available in all markets where RealGUIDE is sold, enhancing ZimVie's current RealGUIDE software suite for treatment planning and implant restoration. RealGUIDE 5.4 now helps users manage procedural risk more effectively and plan complex cases in a fraction of the time. The most significant enhancement in this version is one-click nerve detection and automated bone and tooth segmentation. This empowers clinicians with greater case insights and treatment planning confidence
PALM BEACH GARDENS, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced the U.S. launch of its GenTek® Genuine Restorative Components product portfolio. The launch expands ZimVie's portfolio of end-to-end prosthetic offerings and follows the recent receipt of FDA 510(k) clearance. ZimVie first launched the GenTek portfolio in Europe in 2019 and has seen tremendous success in that market to date. The introduction of GenTek to the U.S. market brings a broad offering of differentiated restorative components to the ZimVie product family. The GenTek restorative portfolio is comprised of Ti-Bases, pre-milled ab
PALM BEACH GARDENS, Fla., July 18, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the second quarter 2024 after market close on Thursday, August 1, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com About ZimVie ZimVie is a global life sciences leader in the dental market that develops, manufa
PALM BEACH GARDENS, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced that the company will be participating in two upcoming investor conferences. ZimVie will be presenting at the upcoming Stifel 2024 Jaws & Paws Conference. ZimVie's management is scheduled to present on Thursday, May 30, 2024, at 11:30 a.m. Eastern Time. ZimVie's management will also be presenting at the 45th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 12, 2024, at 3:20 p.m. Eastern Time. Interested parties may access a live audio webcast of the presentations by visiting the "Investors" section of the company's
Third Party Net Sales from Continuing Operations of $118.2 millionNet Loss from Continuing Operations of ($11.5) million; Net Loss margin of (9.7%) Adjusted EBITDA[1] from Continuing Operations of $12.5 million; Adjusted EBITDA[1] margin of 10.5%Completed sale of spine business for $375 million and repaid $275 million of debt on April 1, 2024 PALM BEACH GARDENS, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2024. Management will host a corresponding conference call today, May 8, 2024, at 4:30 p.m. Eastern Time. "We have driven great progress in 2024 to
PALM BEACH GARDENS, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the first quarter 2024 after market close on Wednesday, May 8, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com About ZimVie ZimVie is a global life sciences leader in the dental market that develops, manufact
SC 13G - ZimVie Inc. (0001876588) (Subject)
SC 13G/A - ZimVie Inc. (0001876588) (Subject)
SC 13G/A - ZimVie Inc. (0001876588) (Subject)
SC 13G - ZimVie Inc. (0001876588) (Subject)
SC 13G - ZimVie Inc. (0001876588) (Subject)
SC 13G/A - ZimVie Inc. (0001876588) (Subject)
SC 13G/A - ZimVie Inc. (0001876588) (Subject)
SC 13G/A - ZimVie Inc. (0001876588) (Subject)
SC 13G/A - ZimVie Inc. (0001876588) (Subject)
SC 13G/A - ZimVie Inc. (0001876588) (Subject)
ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced the U.S. launch of its GenTek® Genuine Restorative Components product portfolio. The launch expands ZimVie's portfolio of end-to-end prosthetic offerings and follows the recent receipt of FDA 510(k) clearance. ZimVie first launched the GenTek portfolio in Europe in 2019 and has seen tremendous success in that market to date.
Shares of Domino’s Pizza, Inc. (NYSE:DPZ) fell sharply during Thursday's session after the company reported mixed quarterly results. The company reported second-quarter FY24 sales growth of 7.1% year-on-year to $1.097 billion, missing the analyst consensus estimate of $1.103 billion. The company is temporarily suspending its guidance metric of 1,100+ global net stores growth until the full effect of DPE's store opens and closures on international net store growth are known. Domino’s Pizza shares dipped 11.2% to $420.36 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Onconetix, Inc. (NASDAQ:ONCO) climbed 97.6% to $0.2944. On July 15, Oncon
U.S. stocks were higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Cintas Corporation (NASDAQ:CTAS) rose during Thursday's session after the company reported better-than-expected quarterly EPS and revenues. Cintas reported fourth-quarter earnings per share of $3.99, beating the street view of $3.80. The company registered quarterly revenues of $2.471 billion, beating the street view of $2.468 billion, according to data from Benzinga Pro. Cintas shares gained 5.3% to $758.25 on Thursday. Here are some other big stocks recording gains in today’s session. Chuy’s Holdings, Inc. (NASDAQ:CHUY) shares gained 47.6% to $37.29 after the company and Darde
Needham analyst David Saxon reiterates ZimVie (NASDAQ:ZIMV) with a Buy and maintains $20 price target.
- Bloomberg
Gainers Akanda (NASDAQ:AKAN) shares rose 177.7% to $0.37 during Friday's pre-market session. The company's market cap stands at $11.7 million. Scorpius Holdings (AMEX:SCPX) stock increased by 28.17% to $0.13. The market value of their outstanding shares is at $4.6 million. NovaBay Pharmaceuticals (AMEX:NBY) shares moved upwards by 27.0% to $0.15. The market value of their outstanding shares is at $5.7 million. ZimVie (NASDAQ:ZIMV) shares moved upwards by 23.61% to $20.99. The company's market cap stands at $572.7 million. Kintara Therapeutics (NASDAQ:KTRA) stock moved upwards by 17.16% to $0.17. The market value of their outstanding shares is at $6.6 million. As per the press release, Q
Needham analyst David Saxon upgrades ZimVie (NASDAQ:ZIMV) from Hold to Buy.